semaj83/ctmatch_classification huggingface dataset:
Patient description: A 52-year-old African American man with a history of heavy smoking and drinking, describes progressive dysphagia that began several months ago. He first noticed difficulty swallowing meat. His trouble swallowing then progressed to include other solid foods, soft foods, and then liquids. He is able to locate the point where food is obstructed at the lower end of his sternum. He has lost a total of 25 pounds.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Esophageal Adenocarcinoma (UICC TNM7) Adenocarcinoma of the Esophagogastric Junction Histologically proven adenocarcinoma of the esophagus according to the Union internationale contre le cancer (UICC) TNM7 definition. Both tumors of the esophagus and tumors of which the epicentre is within 5 cm of the esophagogastric junction and also extend into the esophagus are eligible for into the trial in case of adenocarcinomatous histology. Translated to Siewerts Classification of esophagogastric adenocarcinoma all Type AEG 1 are eligible. Type AEG 2 and Type AEG 3 are eligible in case of tumorous esophageal infiltration Pre-treatment stage cT1N+ M0 or cT2-4a N0/N+, M0 (In case of pre-treatment stage cT4a curative resectability has to be explicitly verified by the local surgical investigator prior to randomisation) Age ≥ 18 years No prior abdominal or thoracic radiotherapy ECOG Performance status 0-2 Adequate cardiac function. Patients with a cardiac history should have a cardiology review and should have a left ventricular ejection fraction > 50% (as determined by echocardiography) Adequate respiratory function (pulmonary function tests completed with FEV1 > 1.5L) Adequate bone marrow function (WBC>3x10^9/l; Hb>9g/dl; platelets >100x10^9/l) Adequate renal function (GFR>60ml/min) and Adequate liver function (Total bilirubin <1.5x Upper level of Normal (ULN); AST <2.5x ULN and ALT <3x ULN  Patients with tumors of squamous, adenosquamous or other non-adenocarcinoma histology Patients with advanced inoperable or metastatic esophageal adenocarcinoma Esophageal adenocarcinoma cT1N0 and cT4b Esophageal adenocarcinoma cT4a evaluated as not curatively resectable by the local surgical investigator Gastric carcinoma (according to UICC TNM7) Prior chemotherapy for gastrointestinal cancer Clinically-significant (active) cardiac disease (e.g. symptomatic coronary artery disease or myocardial infarction within last 12 months) Clinically-significant lung disease (FEV1 <1,5l) Peripheral neuropathy Grade >1 Pregnant and lactating women, or patients of reproductive potential who are not using effective birth control methods. If barrier contraceptives are used, they must be continued throughout the study by both sexes
Patient description: A 52-year-old African American man with a history of heavy smoking and drinking, describes progressive dysphagia that began several months ago. He first noticed difficulty swallowing meat. His trouble swallowing then progressed to include other solid foods, soft foods, and then liquids. He is able to locate the point where food is obstructed at the lower end of his sternum. He has lost a total of 25 pounds.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Esophageal pathologically or cytology diagnosed phase II-III esophageal carcinoma or IV thoracic segments carcinoma with the supraclavicular lymph nodes metastasis with the measureable lesion of the newly diagnosed the esophageal carcinoma age 18-75 years old ECOG≤2 Expect survival date ≥3 months without serious diseases of important organs signature in the inform consent  pregnant or breast-feeding women or using a prohibited contraceptive method with psychiatric diseases with serious diseases or uncontrolled infection with history of other tumors participation other clinical trials within 1 month prior to in the trial not the first antitumor treatment
Patient description: An 8-year-old male presents in March to the ER with fever up to 39 C, dyspnea and cough for 2 days. He has just returned from a 5 day vacation in Colorado. Parents report that prior to the onset of fever and cough, he had loose stools. He denies upper respiratory tract symptoms. On examination he is in respiratory distress and has bronchial respiratory sounds on the left. A chest x-ray shows bilateral lung infiltrates.

Clinical trial eligibility criteria: eligible ages (years): 13.0-999.0,  HIV Infections Patients may be eligible for this study if they Are 13 years of age or older (consent of parent or guardian required if under the age of 18) Are HIV-positive Have either: (1) no previous experience with anti-HIV treatment (defined as no previous protease inhibitor or nonnucleoside reverse transcriptase inhibitor use, 1 week or less of lamivudine use, and 4 weeks or less of cumulative nucleoside reverse transcriptase inhibitor use) or (2) current or previous enrollment in a qualifying CPCRA study
Patient description: An 8-year-old male presents in March to the ER with fever up to 39 C, dyspnea and cough for 2 days. He has just returned from a 5 day vacation in Colorado. Parents report that prior to the onset of fever and cough, he had loose stools. He denies upper respiratory tract symptoms. On examination he is in respiratory distress and has bronchial respiratory sounds on the left. A chest x-ray shows bilateral lung infiltrates.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Brain and Central Nervous System Tumors Histologically or cytologically confirmed glioblastoma multiforme Some oligodendroglial elements allowed provided they make up < 25% of the tumor Recurrent disease documented by MRI after prior radiotherapy At least 1 bidimensionally measurable target lesion ≥ 2 cm by MRI Undergone prior surgery for recurrent primary brain tumor more than 3 months before study entry Must have a clearly limited target lesion ≥ 2 cm OR evidence of progressive and measurable target lesion OR a second measurable target lesion outside the surgical area Age Over 18 Performance status Karnofsky 70-100%
Patient description: An 8-year-old male presents in March to the ER with fever up to 39 C, dyspnea and cough for 2 days. He has just returned from a 5 day vacation in Colorado. Parents report that prior to the onset of fever and cough, he had loose stools. He denies upper respiratory tract symptoms. On examination he is in respiratory distress and has bronchial respiratory sounds on the left. A chest x-ray shows bilateral lung infiltrates.

Clinical trial eligibility criteria: eligible ages (years): 10.0-999.0,  Anemia, Sickle Cell Each subject must meet all of the following during the screening process in order to participate in the study Patient must have a diagnosis of SCD (known SS, S-Beta-thalassemia or other hemoglobinopathies causing sickle cell disease). Patients with disease due to Hgb SC are not permitted Must present to the ED/EC or other appropriate unit in VOC Greater than or equal to 10 years old Written informed consent/assent has been obtained  Subjects meeting any of the following during baseline evaluation will be excluded from entry into the study Exposure to therapeutic nitric oxide within the past 12 hours Patient has received sildenafil or other phosphodiesterase 5 inhibitors, therapeutic L-arginine, nitroprusside or nitroglycerine within the past 12 hours Patient has received previous ED/EC or other appropriate unit treatment for a vaso-occlusive crisis less than 48 hours or hospitalization less than 14 days ago (patients transferred directly from another ED or clinic may be enrolled) Patient has visited the ED/EC or other appropriate unit greater than 10 times in the past year having a vaso-occlusive crisis Patients presenting with clinically diagnosed bacterial infection (e.g., osteomyelitis, pneumonia, sepsis or meningitis) Patients who are currently enrolled in any other investigational drug study except for hydroxyurea studies Pregnant women (urine HCG + )/ nursing mothers Patients who have received an exchange transfusion (not simple transfusion) in the last 30 days or are on a chronic simple or exchange transfusion program Suspected splenic sequestration
Patient description: An 8-year-old male presents in March to the ER with fever up to 39 C, dyspnea and cough for 2 days. He has just returned from a 5 day vacation in Colorado. Parents report that prior to the onset of fever and cough, he had loose stools. He denies upper respiratory tract symptoms. On examination he is in respiratory distress and has bronchial respiratory sounds on the left. A chest x-ray shows bilateral lung infiltrates.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Candidiasis Non-pregnant subjects >/= 18 years of age; admission to the ICU during the preceding 3 days (minimum of 2 days in ICU) and expected to stay in the ICU a minimum of 2 additional days; subjects must have at least 1 of the following: received at least one other dose of any systemic antibiotic on any one of the ICU days before study entry and continue to receive antibiotics at the time of enrollment, and/or presence of a central venous catheter at the time of enrollment and for one additional day during the current ICU stay, and at least 2 of the following: use of total parenteral nutrition on any of Days 1-4 of ICU stay; any type of dialysis on any of Days 1-4 of ICU stay; any in-patient surgery done under general anesthesia or epidural block in the 7 days prior to or on ICU admission*; pancreatitis (documented by computed tomography (CT) scan or lipase >1,000 u/L) in the 7 days prior to or on ICU admission; more than 1 dose of systemic steroids (prednisone equivalent dose >/=20 mg per dose) in the 7 days prior to or on ICU admission; and/or use of more than 1 dose of other systemic immunosuppressive agents (such as azathioprine, tacrolimus, sirolimus, mycophenolate, monoclonal antibodies, and tumor necrosis factor [TNF] immunomodulators) in the 7 days prior to or on ICU admission Excludes placement of vascular catheters  Subjects with an allergy or intolerance to caspofungin or other echinocandin analog; absolute neutrophil count <500/mm3 at entry or likely to develop such a count during therapy; diagnosis of HIV, aplastic anemia, or chronic granulomatous disease; moderate or severe hepatic insufficiency as defined by a Child Pugh score of 7 or greater or cirrhosis due to any cause; pregnancy or breastfeeding; subjects unlikely to survive more than 2 days; subjects who have received systemic antifungal therapy within 7 days prior to study entry; subjects with documented active, proven, or probable invasive fungal infection within 7 days prior to study entry; subjects previously enrolled into this trial; subjects currently receiving another investigational agent or who have received an investigational agent within the 7 days prior to study entry; subjects in the ICU 5 or more days prior to enrollment into this study
Patient description: An 8-year-old male presents in March to the ER with fever up to 39 C, dyspnea and cough for 2 days. He has just returned from a 5 day vacation in Colorado. Parents report that prior to the onset of fever and cough, he had loose stools. He denies upper respiratory tract symptoms. On examination he is in respiratory distress and has bronchial respiratory sounds on the left. A chest x-ray shows bilateral lung infiltrates.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  HIV Infections Presently participating, previously participated in, or has given informed consent for participation in a qualifying CPCRA clinical trial Signed informed consent
Patient description: An 8-year-old male presents in March to the ER with fever up to 39 C, dyspnea and cough for 2 days. He has just returned from a 5 day vacation in Colorado. Parents report that prior to the onset of fever and cough, he had loose stools. He denies upper respiratory tract symptoms. On examination he is in respiratory distress and has bronchial respiratory sounds on the left. A chest x-ray shows bilateral lung infiltrates.

Clinical trial eligibility criteria: eligible ages (years): 18.0-35.0,  Respiratory Tract Infections Chronic Bronchitis Pneumonia Subjects meeting all of the following will be considered for enrollment into the study Male and female adult outpatient subjects diagnosed with AECB or CAP Female subjects must be either postmenopausal for ≥ 1 year or surgically incapable of bearing children. Women of childbearing potential must have a normal menstrual flow ≤ 1 month before study entry, a negative serum pregnancy test immediately prior to study entry, and meet the for acceptable birth control Informed consent must be obtained in writing for all subjects upon enrollment Subjects will have a diagnosis of AECB or CAP, as defined below AECB-Specific Subjects greater than or equal to 35 years of age Subjects with a documented history of chronic bronchitis: with a basal forced expiratory volume in one second (FEV1) < 70% and > 35%; who have had at least one or more AECB in the previous year; and with FEV1/forced vital capacity (FVC) < 70% Subjects with a clinical diagnosis of AECB, presumed to be due to bacterial infection based on increased sputum purulence with either increased dyspnea or sputum volume Subjects producing spontaneous sputum  Subjects presenting with any of the following will not be included in the study Subjects with a known history of congenital long-QTc syndrome Subjects who are pregnant or breast-feeding Subjects who have hypersensitivity to telithromycin, azithromycin, or the macrolide classes of antibiotics Subjects who require or receive treatment with rifampin (Rifadin), phenytoin (Dilantin), carbamazepine (Carbatrol, Tegretol), phenobarbital, or St. John's wort (herbal supplement) within 2 weeks prior to Visit 1 or during the study Subjects who require treatment during the study with ergot alkaloid derivatives, cisapride (Propulsid), pimozide (Orap), bromocriptine, cabergoline (Dostinex), or pergolide (Permax) Subjects who have previously participated in this study Subjects with a previous history of myasthenia gravis Subjects with current acute respiratory failure or subjects who require aggressive airway management Hospitalized subjects and subjects from institutional care facilities
Patient description: An 8-year-old male presents in March to the ER with fever up to 39 C, dyspnea and cough for 2 days. He has just returned from a 5 day vacation in Colorado. Parents report that prior to the onset of fever and cough, he had loose stools. He denies upper respiratory tract symptoms. On examination he is in respiratory distress and has bronchial respiratory sounds on the left. A chest x-ray shows bilateral lung infiltrates.

Clinical trial eligibility criteria: eligible ages (years): 1.0-5.0,  Tick-borne Encephalitis Male and female children will be eligible for participation in this study if they are 1 year (from the 1st birthday) to 6 years (to the last day before the 6th birthday) old they are clinically healthy their legal representative understands the nature of the study, agrees to its provisions and gives written informed consent their legal representative agrees to keep a Volunteer Diary  Children will be excluded from participation in this study if they have a history of any previous TBE vaccination have a history of TBE infection or show evidence of a latent TBE infection (as demonstrated by screening ELISA > 126 VIEU/ml and / or neutralization test > 1:10) have a history of allergic reactions, in particular to one of the components of the vaccine have received antipyretics within 4 hours prior to the first TBE vaccination suffer from a disease that cannot be effectively treated or stabilized suffer from a disease (e.g. autoimmune disease) or are undergoing a form of treatment that can be expected to influence immunological functions suffer from chronic, degenerative and / or inflammatory disease of the central nervous system are known to be HIV positive (a special HIV test is not required for the purpose of the study) suffer from a febrile illness at study entry
Patient description: An 8-year-old male presents in March to the ER with fever up to 39 C, dyspnea and cough for 2 days. He has just returned from a 5 day vacation in Colorado. Parents report that prior to the onset of fever and cough, he had loose stools. He denies upper respiratory tract symptoms. On examination he is in respiratory distress and has bronchial respiratory sounds on the left. A chest x-ray shows bilateral lung infiltrates.

Clinical trial eligibility criteria: eligible ages (years): 6.0-15.0,  Tick-borne Encephalitis Male and female children will be eligible for participation in this study if they are 6 years (from the 6th birthday) to 16 years old (to the last day before the 16th birthday) they are clinically healthy their legal representative and if older than 8 years the volunteer understands the nature of the study, agrees to its provisions and gives written informed consent their legal representative agrees to keep a Volunteer Diary For safety reasons female volunteers capable of bearing children have to fulfill the following at study start negative pregnancy test at study start they agree to employ adequate birth control measures for the duration of the study  Children will be excluded from participation in this study if they have a history of any previous TBE vaccination have a history of TBE infection or show evidence of a latent TBE infection (as demonstrated by screening ELISA > 126 VIEU/ml and / or neutralization test > 1:10) have a history of allergic reactions, in particular to one of the components of the vaccine have received antipyretics within 4 hours prior to the first TBE vaccination suffer from a disease that cannot be effectively treated or stabilized suffer from a disease (e.g. autoimmune disease) or are undergoing a form of treatment that can be expected to influence immunological functions suffer from chronic, degenerative and / or inflammatory disease of the central nervous system are known to be HIV positive (a special HIV test is not required for the purpose of the study) suffer from a febrile illness at study entry
Patient description: An 8-year-old male presents in March to the ER with fever up to 39 C, dyspnea and cough for 2 days. He has just returned from a 5 day vacation in Colorado. Parents report that prior to the onset of fever and cough, he had loose stools. He denies upper respiratory tract symptoms. On examination he is in respiratory distress and has bronchial respiratory sounds on the left. A chest x-ray shows bilateral lung infiltrates.

Clinical trial eligibility criteria: eligible ages (years): 16.0-65.0,  Encephalitis, Tick-borne Male and female volunteers were eligible for participation in this study if they Were 16 years (from the 16th birthday) to 65 years (to the last day before the 65th birthday) old Were clinically healthy Had a negative pregnancy test at the first medical examination, if female and capable of bearing children Agreed to employ adequate birth control measures for the duration of the study, if female and capable of bearing children Provided written informed consent For volunteers under 18 years of age written informed consent of the parents / guardian was available Agreed to keep a volunteer diary  History of any previous TBE vaccination History of TBE infection or show evidence of latent TBE infection (as demonstrated by screening ELISA > 126 VIEU/ml) History of allergic reactions, in particular to one of the components of the vaccine Previously received volume substitution with a product containing polygeline (stabilizer in Received antipyretics within 4 hours prior to the first TBE vaccination Suffer from a disease that cannot be effectively treated or stabilized Suffering from a disease (e.g. autoimmune disease) or were undergoing any form of treatment that could be expected to influence immunological functions Suffering from chronic, degenerative and/or inflammatory disease of the central nervous system Using any immunosuppressive drugs (e.g. local or systemic corticosteroids, chemotherapeutics) Had a known or suspected problem with drug or alcohol abuse (> 4 liters wine / week or equivalent level of other alcoholic beverages)
Patient description: An 8-year-old male presents in March to the ER with fever up to 39 C, dyspnea and cough for 2 days. He has just returned from a 5 day vacation in Colorado. Parents report that prior to the onset of fever and cough, he had loose stools. He denies upper respiratory tract symptoms. On examination he is in respiratory distress and has bronchial respiratory sounds on the left. A chest x-ray shows bilateral lung infiltrates.

Clinical trial eligibility criteria: eligible ages (years): 1.0-15.0,  Tick-borne Encephalitis Male and female children and adolescents will be eligible for participation in this study if they are aged 1 year (from the 1st birthday) to < 16 years (to the last day before the 16th birthday) they are clinically healthy, (i. e. the physician would have no reservations vaccinating with FSME-IMMUN NEW outside the scope of a clinical trial) their parents/legal guardians understand the nature of the study and agree to its provisions written informed consent is available from both parents/legal guardians for Germany/Austria: additional written informed consent is available for children older than 8 years they or their parents/legal guardians agree to keep a volunteer diary For safety reasons, female volunteers who have reached sexual maturity at study start have to meet the following additional negative pregnancy test at study entry  Children and adolescents will be excluded from participation in this study if they have a history of any TBE vaccination have a history of TBE infection have a history of allergic reactions to one of the components of the vaccine suffer from a disease (e.g. autoimmune disease) or are undergoing a form of treatment (e.g. systemic corticosteroids, chemotherapeutics) that can be expected to influence immunological functions are known to be HIV positive (a special HIV test is not required for the purpose of the study) have received banked blood or immunoglobulins within one month of study entry have a history of vaccination against yellow fever and/or Japanese B-encephalitis suffer from hemorrhagic diathesis are participating simultaneously in another clinical trial